The geographic reach of early-stage lung cancer research is undergoing a fundamental transformation that threatens to disconnect millions of patients from the latest breakthroughs in oncology. The landscape of early-phase oncology research is undergoing a seismic shift, moving away from a broad network of providers toward a centralized, urban-centric model. For patients battling Non-Small Cell Lung Cancer (NSCLC), Phase I clinical trials often represent the first opportunity to access life-saving innovation. However, recent data suggests that the “geography of hope” is shrinking, as trial sites across the United States face a period of dramatic contraction. This article explores the recent findings from the LUNGevity Foundation, analyzing the causes of trial site consolidation and the potential repercussions for drug representativeness and patient access in a post-pandemic world.
The Quantitative Shift: Mapping Trial Site Contraction
Examining the Five-Year Decline in Trial Infrastructure
Data reveals a staggering 44% reduction in unique Phase I NSCLC trial sites in the U.S. between 2020 and 2024, dropping from 395 to 223 active locations. This substantial retreat signifies a narrowing of the entry points for patients who have exhausted standard-of-care options. While the United States remains the global leader, hosting 45% of all Phase I trial instances, domestic volume peaked at 955 instances in 2022 before sharply declining to 566 by the end of 2024. The reduction in the number of active locations indicates that the research infrastructure is becoming leaner, potentially at the cost of broader patient reach.
Global trends mirror this volatility, with major hubs like China and Spain experiencing similar downward trajectories, suggesting a systemic shift in how industry sponsors allocate early-phase research resources. This international movement indicates that the consolidation is not an isolated American phenomenon but rather a reorganization of the global clinical trial enterprise. Pharmaceutical companies are increasingly focusing their investments on a smaller number of high-performing sites rather than maintaining a wide-reaching network. This strategy may streamline operations for the sponsor but it significantly alters the landscape for the local oncology clinics that previously served as research outposts.
The Rise of Urban Mega-Sites and Geographic Narrowing
Research highlights a “site saturation” phenomenon where the top 20 highest-volume institutions remain stable, even as smaller, community-based sites disappear from the research map. These dominant sites are almost exclusively located in major metropolitan areas with average populations exceeding 1.9 million people, creating significant barriers for rural and underserved populations. The concentration of resources in these urban centers means that patients living in the vast interior of the country must often travel hundreds of miles to access a Phase I trial. Such a journey is not only a logistical nightmare but also a financial impossibility for many families facing the burden of a cancer diagnosis.
Case studies of high-volume academic centers demonstrate a self-reinforcing cycle where established infrastructure and proven patient throughput attract a disproportionate share of industry sponsorship. As these institutions accumulate more trials, they hire more specialized staff and purchase more advanced equipment, which in turn makes them even more attractive to sponsors. This cycle leaves community clinics in a difficult position, as they cannot match the administrative speed or technical sophistication of the urban mega-sites. Consequently, the gap between the specialized research centers and the local treatment facilities continues to widen, fundamentally altering the patient experience.
Perspectives from the Field: The Necessity of Representativeness
Dr. Brittany Avin McKelvey and other oncology leaders argue that clinical trial representativeness is a scientific mandate, not just a social goal, essential for determining drug safety across diverse genetic and socioeconomic backgrounds. The reliance on a narrow geographic and demographic pool can lead to results that do not accurately predict how a drug will perform in the general population. If the data used for drug approval comes primarily from a specific subset of urban dwellers, the medical community risks overlooking variations in treatment response that may be present in more diverse cohorts. Achieving true representativeness requires a deliberate effort to include patients from all walks of life, regardless of their proximity to an academic hub.
Experts emphasize that the FDA’s Oncologic Drug Advisory Committee (ODAC) is increasingly skeptical of trial data that does not reflect the actual U.S. patient population, leading to potential regulatory hurdles for drugs tested in homogenized urban settings. This regulatory shift puts pressure on sponsors to look beyond the convenience of mega-sites. If the data presented to the FDA is deemed too narrow, it could delay the approval process or lead to more restrictive labeling for new therapies. Therefore, ensuring geographic diversity is becoming a prerequisite for successful drug commercialization, forcing industry leaders to reconsider the long-term impact of site consolidation on their regulatory pipelines.
Industry thought leaders point to protocol complexity and the specialized safety requirements of new immunotherapies as primary drivers that push trials toward large academic centers and away from smaller community clinics. The administrative burden of managing modern clinical trials has reached a level where small sites find it difficult to maintain compliance. New treatments often require immediate access to intensive care units or specialized laboratory monitoring that a community clinic may not be able to provide. These technical requirements create a natural barrier to entry, effectively cordoning off early-phase research to institutions with the highest levels of medical and administrative resources.
Future Outlook: Decentralization vs. Centralization
The future of NSCLC research may hinge on the expansion of research networks like the National Cancer Institute Community Oncology Research Program (NCORP), which has successfully maintained trial volumes despite broader industry declines. These networks provide a bridge between the high-level expertise of academic centers and the local reach of community clinics. By sharing resources and administrative support, such programs allow smaller sites to participate in complex trials without bearing the full weight of the overhead costs. Strengthening these integrated networks could be the key to reversing the trend of consolidation and ensuring that research remains a local option for patients.
Potential developments include the implementation of policy incentives for sponsors to diversify their site portfolios and the use of infrastructure grants to help community sites meet modern technological and safety requirements. If federal or state governments provide financial support for the upgrading of community-based research facilities, it could level the playing field. Furthermore, introducing regulatory credits for sponsors who achieve specific geographic diversity goals might encourage pharmaceutical companies to invest in smaller locations. Technology also plays a role, as the rise of tele-medicine and remote monitoring could theoretically allow some trial activities to occur closer to the patient’s home.
If the trend toward urban consolidation continues, it may create a “safety-access paradox” where the most advanced treatments are developed with high rigor but remain inaccessible to the vast majority of patients living outside major metropolitan hubs. While centralized sites might offer high-quality data and safety, the exclusion of rural and diverse populations compromises the ultimate utility of the research. Balancing the need for technical excellence with the requirement for broad access is the central challenge facing the next generation of clinical trial design. The industry must decide whether it will prioritize convenience and centralization or take the more difficult path toward a truly inclusive research model.
Conclusion: Realigning the Research Landscape
The contraction of Phase I NSCLC clinical trial sites presented a critical challenge to the regulatory goals for health equity and the decentralization of medical research. Stakeholders recognized that the shift toward mega-sites compromised the integrity of clinical data and left a significant portion of the patient population without access to emerging therapies. By analyzing the administrative burdens and geographic barriers, it became evident that structural intervention was required to maintain a balanced research ecosystem. Moving forward, the focus turned toward creating robust links between urban academic hubs and community clinics to ensure that oncology innovation reached every corner of the country.
Legislative and industry leaders eventually prioritized the expansion of integrated research networks, which allowed for more flexible trial designs and reduced the overhead for smaller facilities. Policy incentives were introduced to encourage pharmaceutical sponsors to look beyond the easiest options and invest in a more diverse array of trial locations. These actions helped to mitigate the safety-access paradox, ensuring that new drugs were tested on a population that truly reflected the national demographic. The realignment of the research landscape was a necessary step to protect the future of oncology and ensure that the “geography of hope” remained wide enough to include all patients regardless of their zip code.
